Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia has received a milestone payment from Wyeth Pharmaceuticals, a division of Wyeth, for progress made in identifying a systemically administered inhibitor of JAK3 kinase.
Subscribe to our email newsletter
The JAK3 kinase is being evaluated for the treatment of immunological and inflammatory diseases.
The JAK3 is selectively expressed in certain hematopoietic cells and is involved in T-cell activation. The inhibition of JAK3 kinase has been shown to modulate disease outcomes in both preclinical animal models and clinical studies. Potential indications for an inhibitor of JAK3 include rheumatoid arthritis, transplantation and psoriasis.
Joseph Mollica, president and CEO of Pharmacopeia, said: “We are pleased with the progress Wyeth and Pharmacopeia have made in advancing this program. The advances are critical to the growth of our JAK3 inhibitor program, and we will continue working closely with Wyeth to realize the therapeutic potential of JAK3 inhibitor-based products.”